CLEVER CHOICE AUTO-CODE PRO BLOOD GLUCOSE MONITORING SYSTEM MODEL TD-4267
Applicant
Taidoc Technology Corporation
Product Code
CGA · Clinical Chemistry
Decision Date
Apr 1, 2010
Decision
SESE
Submission Type
Special
Regulation
21 CFR 862.1345
Device Class
Class 2
Attributes
Pediatric
Intended Use
The CLEVER CHOICE Auto-Code Pro Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood samples from the finger and the following alternative sites: palm, forearm, upper arm, calf and thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus. The CLEVER CHOICE Auto-Code Pro Blood Glucose Monitoring System cannot be used on neonates. The alternative site testing in above systems can be used only during steady-state blood glucose conditions.
Device Story
System measures glucose concentration in fresh capillary whole blood; utilizes electrochemical meter and dry reagent biosensor test strips. Amperometric principle: electrical current generated by glucose-reagent reaction is proportional to glucose concentration. Used by healthcare professionals and patients at home for diabetes management. Provides quantitative glucose readings to assist in monitoring diabetes control programs. Not for diagnostic or screening purposes.
Clinical Evidence
Bench testing only. No clinical data provided. Substantial equivalence supported by design control activities, risk analysis, and verification/validation of software and hardware modifications.
Technological Characteristics
Electrochemical glucose monitoring; USB data interface; physical meter enclosure with integrated display and navigation buttons (M, S, up/down). Software modified to remove coding display. Sterilization: N/A (meter).
Indications for Use
Indicated for quantitative blood glucose measurement in patients with diabetes mellitus. Suitable for use by healthcare professionals and patients at home. Samples: fresh capillary whole blood from finger, palm, forearm, upper arm, calf, or thigh. Contraindications: Not for use on neonates; alternative site testing only during steady-state glucose conditions; not for diagnosis or screening of diabetes.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
Predicate Devices
FORA G30 blood glucose monitoring system (K090187)
Related Devices
K093005 — FORA G72 BLODO GLUCOSE MONITORING SYSTEM/TD-4264 BLOOD GLUCOSE MONITORING SYSTEM, MODEL TD-4264 · Taidoc Technology Corporation · Feb 5, 2010
K094005 — FORA G31A/TD-4256A BLOOD GLUCOSE MONITORING SYSTEM AND FORA G31B/TD-4256B BLOOD GLUCOSE MONITORING SYSTEM · Taidoc Technology Corporation · May 5, 2010
K072854 — DIACHEX BASIC BLOOD GLUCOSE MONITORING SYSTEM, DIACHEX SUPERB BLOOD GLUCOSE MONITORING SYSTEM · Tyson Bioresearch, Inc. · Jun 30, 2008
K060467 — PRODIGY BLOOD GLUCOSE TEST SYSTEM · Diagnostic Devices, Inc. · Jul 13, 2006
Submission Summary (Full Text)
{0}
SPECIAL 510(k): Device Modification
ODE Review Memorandum (Decision Making Document is Attached)
To: THE FILE
RE: DOCUMENT NUMBER k093506
This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable (delete/add items as necessary):
1. The name and 510(k) number of the SUBMITTER'S previously cleared device. (For a preamendments device, a statement to this effect has been provided.)
TaiDoc Technology Corporation FORA G30 blood glucose monitoring system, k090187
2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).
3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.
This change was for :
A) Modification to the software to: remove the one pre-set code from displaying on the screen to having no coding information displayed when the test strip is inserted
B) Removing the C button (control) and merging this function into the M button
C) Moving the position of the S button
D) Adding up and down buttons
E) Changing the data port connection RS232 interface cable to a USB cable
F) Physical appearance of meter
G) Labeling modified to reflect changes of device
4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, physical characteristics, and performance characteristics.
5. A Design Control Activities Summary which includes:
a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied
c) A declaration of conformity with design controls. The declaration of conformity should include:
i) A statement signed by the individual responsible, that, as required by the risk analysis, all verification and validation activities were performed by the designated individual(s) and the results demonstrated that the predetermined acceptance criteria were met, and
ii) A statement signed by the individual responsible, that the manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review.
6. A Truthful and Accurate Statement, a 510(k) Summary or Statement and the Indications for Use Enclosure (and Class III Summary for Class III devices).
The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.